Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Large Growth in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 101,700 shares, agrowthof2,442.5% from the July 15th total of 4,000 shares. Based on an average daily volume of 460,100 shares, the days-to-cover ratio is currently 0.2 days. Approximately0.0% of the company’s shares are short sold. Approximately0.0% of the company’s shares are short sold. Based on an average daily volume of 460,100 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Separately, Nomura Securities raised Daiichi Sankyo to a “strong-buy” rating in a research note on Friday, June 6th.

Daiichi Sankyo Stock Performance

DSNKY opened at $24.41 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.85 and a current ratio of 2.53. Daiichi Sankyo has a 52-week low of $20.92 and a 52-week high of $42.48. The firm has a market cap of $46.24 billion and a P/E ratio of 23.70. The business’s fifty day moving average is $23.74 and its 200-day moving average is $24.23.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.